Clinical Significance of HPV in Oropharyngeal Squamous Cell Carcinoma
-
摘要:
目的 探讨HPV与口咽鳞癌的临床意义。 方法 选择2010年1月至2019年12月在云南省肿瘤医院诊治并符合入组标准的129例口咽癌患者作为研究对象。使用HPV16/18型DNA探针、HPV 6/11型DNA探针对收集的病理标本进行检测。采用SPSS 24.0统计软件进行数据分析。 结果 HPV阳性率39.53%,全部为高危型HPV 16/18感染;扁桃体区及舌根区阳性率最高;HPV阳性组中发病年龄小于60岁(P = 0.041)、分期为早期(P = 0.001)的病例数明显多于阴性组。而阴性组中长期吸烟病例数明显高于阳性组(P = 0.012)。HPV阳性组的患者治疗有效率高于阴性组。 结论 HPV阳性口咽鳞癌患者较HPV阴性口咽鳞癌患者发病年龄年轻、分期早、长期吸烟人数少,且对放化疗敏感性更高。 Abstract:Objective To explore the clinical significance of HPV in oropharyngeal squamous cell carcinoma. Methods A total of 129 patients who were diagnosed and treated in Yunnan Tumor Hospital and met the inclusion criteria in oropharyngeal cancer from January 2010 to December 2019 were selected as the research subjects. The collected pathological specimens were detected using HPV16/18 DNA probes and HPV 6/11 DNA probes. SPSS 24.0 statistical software was used for data analysis. Results The positive rate of HPV in this study was 39.53%, all of which were high-risk HPV 16/18 infection. The positive rate was highest in tonsil area and tongue root area. The number of cases with the onset age less than 60 years (P = 0.041) and the early stage (P = 0.001) in the HPV positive group was significantly higher than that in the negative group. The number of long-term smoking cases in the negative group was significantly higher than that in the positive group (P = 0.012). The treatment effective rate of patients in the HPV positive group is higher than that in the HPV negative group. Conclusion Compared with HPV-negative oropharyngeal squamous cell carcinoma, patients with HPV-positive oropharyngeal squamous cell carcinoma have a younger onset, early stage, fewer long-term smokers, and are more sensitive to radiotherapy and chemotherapy. -
Key words:
- Oropharyngeal tumor /
- Squamous cell carcinoma /
- Human papillomavirus
-
表 1 云南省肿瘤医院129例HPV 相关口咽癌临床资料比较[n(%)]
Table 1. Comparison of the clinical data of 129 cases of HPV-related oropharyngeal cancer in Yunnan cancer hospital [n(%)]
变量 HPV状态 χ2 P 阳性 阴性 性别 男 45(88.2) 69(88.5) 0.002 0.969 女 6(11.8) 9(11.5) 年龄(岁) ≤60 36(70.6) 41(52.6) 4.164 0.041* > 60 15(29.4) 37(47.4) 长期吸烟史 有 24(47.1) 54(69.2) 6.342 0.012* 无 27(52.9) 24(30.8) 长期饮酒史 有 22(43.1) 39(50.0) 0.583 0.445 无 29(56.9) 39(50.0) T分期 T1~T2 25(49.0) 43(55.1) 0.462 0.497 T3~T4 26(51.0) 35(44.9) N分期 N0~N1 30(58.8) 40(51.3) 0.707 0.401 N2~N3 21(41.2) 38(48.7) 临床分期 I~II 32(62.7) 25(32.1) 11.780 0.001* III~IV 19(37.3) 53(67.9) 病理学分化 高~中分化 30(58.8) 58(74.4) 3.433 0.064 低分化 21(41.2) 20(25.6) 病灶位置 扁桃体 21(41.2) 19(24.4) 5.899 0.117 舌根 13(25.5) 19(24.4) 软腭 3(5.8) 12(15.4) 口咽侧壁及后壁 14(27.5) 28(35.8) *P < 0.05。 表 2 云南省肿瘤医院118例不同 HPV 感染状态口咽癌放化疗治疗效果比较[n(%)]
Table 2. Comparison of radiotherapy and chemotherapy effect of 118 cases of oropharyngeal cancer in different HPV infection states in Yunnan cancer hospital [n(%)]
HPV状态 疗效评估 χ2 P CR PR SD PD 阳性 24(51.1) 14(29.8) 9(19.1) 0(0) 15.002 0.002* 阴性 15(21.1) 30(42.3) 21(29.6) 5(7.0) 总计 39 44 30 5 *P < 0.05。 -
[1] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J]. Int J Cancer,2019,144(8):1941-1953. [2] 陈雪松. 头颈部肿瘤人乳头状瘤病毒感染及其临床特征 [D]. 北京: 北京协和医学院硕士学位论文, 2012. [3] 曲媛,高黎,易俊林,等. 口咽鳞癌 HPV 感染与 p16 表达及放疗预后相关性研究[J]. 中华放射肿瘤学杂志,2014,23(2):135-139. doi: 10.3760/cma.j.issn.1004-4221.2014.02.014 [4] 崔湘凝,张欣,徐婧,等. 口咽鳞癌组织中 HPV16 感染和p16 蛋白表达的临床意义[J]. 现代肿瘤医学,2015,23(13):1813-1818. doi: 10.3969/j.issn.1672-4992.2015.13.09 [5] 王金月. 头颈鳞癌与人乳头状瘤病毒相关性的初步探索 [D]. 吉林: 吉林大学硕士学位论文, 2018. [6] 吴忠强. P16 蛋白表达在口咽部鳞状细胞癌中的临床意义 [D]. 广西: 广西医科大学硕士学位论文, 2019. [7] 张永侠. HPV 相关口咽鳞癌临床预后及肿瘤分子指标的研究 [D]. 北京: 北京协和医学院 博士学位论文, 2013. [8] 黄辉. 口咽部鳞状细胞癌人乳头状瘤病毒感染及 p16 蛋白表达的临床意义 [D]. 北京: 北京协和医学院博士学位论文, 2012. [9] 王凤泽. 口咽癌和口腔癌 HPV 感染状况及与预后关系的研究 [D]. 西安: 第四军医大学硕士学位论文, 2017. [10] Lydiatt W M,Patel S G,O'Sullivan B,et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual[J]. CA Cancer J Clin,2017,67(2):122-137. [11] Liu J,Yang X-l,Zhang S-W,等. 中国口咽癌的发病率、死亡率和时间格局:一项基于人群的研究[J]. 癌症,2019,38(6):272-281. [12] Gillison M L,Trotti A M,Harris J,et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016):a randomised,multicentre,non-inferiority trial[J]. Lancet,2019,393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X [13] Sanders A E,Slade G D,Patton L L. National prevalence of oral HPV infection and related risk factors in the U. S. adult population[J]. Oral Dis.,2012,18(5):430-441. doi: 10.1111/j.1601-0825.2011.01892.x [14] Roman B R,Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck[J]. J Surg Oncol,2021,124(6):920-922. doi: 10.1002/jso.26687 [15] 张洋,张宋安,阿尔孜古丽·吐尔逊,等. 新疆地区不同民族人乳头状瘤病毒感染状态对局限期头颈部鳞状细胞癌预后的影响[J]. 中华口腔医学杂志,2015,50(12):742-745. doi: 10.3760/cma.j.issn.1002-0098.2015.12.008 [16] 蔡永聪. 四川地区头颈鳞癌中人乳头状瘤病毒DNA表达的初步调查 [D]. 广西: 广西医科大学硕士学位论文, 2010. [17] Herrero R,Castellsagué X,Pawlita M,et al. Human papillomavirus and oral cancer:the International Agency for Research on Cancer multicenter study[J]. Journal of the National Cancer Institute,2003,95(23):1772-1783. [18] Hay A,Nixon I J. Recent advances in the understanding and management of oropharyngeal cancer[J]. F1000Res,2008,7:F1000 Faculty Rev-1362. [19] Oliva M,Huang S,Xu W,et al. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy[J]. European Journal of Cancer,2019,118:112-120. doi: 10.1016/j.ejca.2019.06.019 [20] Geltzeiler M,Bertolet M,Albergotti W,et al. Staging HPV-related oropharyngeal cancer:Validation of AJCC-8 in a surgical cohort[J]. Oral Oncology,2018,84:82-87. doi: 10.1016/j.oraloncology.2018.07.013 [21] Kao S,Micklem J,Ofo E,et al. A comparison of oncological outcomes between transoral surgical and non-surgical treatment protocols in the management of oropharyngeal squamous cell carcinoma[J]. The Journal of Laryngologyotology,2018,132(4):349-355. doi: 10.1017/S0022215117000986 [22] Grisar K,Dok R,Schoenaers J,Dormaar T,et al. Differences in human papillomavirus-positive and -negative head and neck cancers in Belgium:an 8-year retrospective,comparative study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2016,121(5):456-460. doi: 10.1016/j.oooo.2015.10.035 [23] Prevc A,Kranjc S,Cemazar M,et al. Dose-modifying factor of radiation therapy with concurrent cisplatin treatment in HPV-positive squamous cell carcinoma:a preclinical study[J]. Radiation Research,2018,189(6):644-651. doi: 10.1667/RR14984.1 [24] 陈永菊,黄子贤,陈睿,等. 人类乳头瘤病毒阳性口咽癌对放疗敏感的研究进展[J]. 口腔疾病防治,2021,29(1):65-68. doi: 10.12016/j.issn.2096-1456.2021.01.011 [25] Fakhry C,Westra W,Li S,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial[J]. Journal of the National Cancer Institute,2008,100(4):261-269. doi: 10.1093/jnci/djn011